IGF1 and hypertrophic cardiomyopathy 1: The importance of IGF-1 and specifically IGF-1 in VSMCS in preventing CMH is highlighted by preclinical studies clearly demonstrating that reduction in circulating IGF-1 levels, or VSMC knockout of Igf1 receptor accelerates and exacerbates the development of CMH [23, 24, 30].